| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/09/2008 | EP1299348B1 Compounds and compositions for delivering active agents |
| 04/09/2008 | EP1140964B1 Connective tissue growth factor (ctgf) fragment |
| 04/09/2008 | EP1082112B1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 04/09/2008 | EP1036175B1 Human brain derived kcnq2 potassium channel |
| 04/09/2008 | CN101160399A Oligonucleotide compositions and their use for the modulation of immune responses |
| 04/09/2008 | CN101160398A Promoter for introducing extracellular substance into mammalian ovum and introduction method |
| 04/09/2008 | CN101160322A Molecules and chimeric molecules thereof |
| 04/09/2008 | CN101160137A Use of CD 25antibody in immunity treatment |
| 04/09/2008 | CN101160129A Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients |
| 04/09/2008 | CN101156949A Synergistic therapeutic compositions of angiotensin i converting enzyme inhibitors and angiotensin ii antagonists and methods |
| 04/09/2008 | CN101156850A Treatment of depression and other affective disorders |
| 04/09/2008 | CN101156843A A capsule for preventing and treating Alzheimer disease as well as its preparing method |
| 04/09/2008 | CN101156837A A method for preparing compound recipe amino acid vitamin micro pill capsule |
| 04/09/2008 | CN100379865C Method and reagents for vaccination which generate a CD8 T cell immune response |
| 04/09/2008 | CN100379758C Streptococcus pneumoniae antigens |
| 04/09/2008 | CN100379752C Antagonists of BMP and TGF beta signalling pathway |
| 04/09/2008 | CN100379751C Regeneration of endogenous myocardial tissue by induction of neovascularization |
| 04/09/2008 | CN100379456C Preparation for the prophylaxis of restenosis |
| 04/09/2008 | CN100379455C Medicine for prevention and treatment of endometeriosis |
| 04/09/2008 | CN100379446C Erythropoietin ameliorates chemotheapy-induced toxicity in vivo |
| 04/09/2008 | CN100379426C Pyrimidine nucleoside and pharmacy usage of pyrimidine nucleotide precursor |
| 04/09/2008 | CN100379423C Topical medicine composite containing cholinergic drug or calcium channel paralyser |
| 04/09/2008 | CN100379421C Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| 04/09/2008 | CN100379413C Preparation for improving the action of receptors |
| 04/09/2008 | CN100379412C Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemia |
| 04/09/2008 | CN100379406C Method for preparing tiny pellets of difficult soluble drugs and formulation containing the pellets |
| 04/08/2008 | US7355093 Transgenic rodent for use as tools in identifying modulator for treatment of diabetes, hypertension, cardiovascular and bone disorders |
| 04/08/2008 | US7355074 Especially calix[4]arene amides, e.g., calix[4]arene tetrabutylamide-1,3-alt; capable of forming a chloride ion channel across a lipid bilayer, and transporting chloride ion across the bilayer |
| 04/08/2008 | US7355069 2-[2-(4-{2-[ethyl(2-fluorobenzyl)amino]-2-oxoethoxy}phenyl)ethoxy]benzoic acid; peroxisome proliferator-activated receptors alfa agonist; antidiabetic, hypotensive agent; obesity, elevated VLDL (Very Low Density Lipoproteins) and reduced HDL (High Density Lipoprotein) concentrations |
| 04/08/2008 | US7355025 Marker molecules associated with lung tumors |
| 04/08/2008 | US7355024 Regulatory sequences for modulation of INGAP expression and reporter constructs |
| 04/08/2008 | US7355019 Cysteine-containing peptide tag for site-specific conjugation of proteins |
| 04/08/2008 | US7355015 Matriptase, a serine protease and its applications |
| 04/08/2008 | US7354948 Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
| 04/08/2008 | US7354941 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes |
| 04/08/2008 | US7354928 Therapeutic treatment with an antiapoptotic agents, antitumor agents, anticarcinogenic agents |
| 04/08/2008 | US7354924 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| 04/08/2008 | US7354919 Isoxazole compositions useful as inhibitors of ERK |
| 04/08/2008 | US7354912 For therapy of osteoporosis |
| 04/08/2008 | US7354895 Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors |
| 04/08/2008 | US7354763 For use in tissue engineering; medical diagnosis; culture of human progenitor cells; isolation |
| 04/08/2008 | US7354738 isolated polypeptide modulates activity of nuclear receptor/ nuclear respiratory factor, brown adipose cell determination/differentiation, mitochondrial activity, biogenesis, fatty acid oxidation |
| 04/08/2008 | US7354736 Intracellular caspase inhibitory polypeptide for use in treatment and prevention of cell proliferative, nervous system and autoimmune disorders |
| 04/08/2008 | US7354709 Diagnosing cancer in mammals; obtain sample cells, monitor expression of collapsin protein, amplified concentration of collapsin indicates cancer |
| 04/08/2008 | US7354606 touchi plant extract and phaseolamin mixture for limiting the absorption of carbohydrates contained in a foodstuff, for promoting weight loss in an individual; nutraceuticals |
| 04/08/2008 | US7354586 Treating arthritis by administering a therapeutically effective amount of an antibody immunospecific for av beta 3; antiarthritic agents;anticarcinogenic agents; antitumor agents; antimetastasis agents; antiinflammatory agents; antibody does not immunoreact with integrins other than av beta 3 |
| 04/08/2008 | US7354579 Method of treating cancer with a VEGF antagonist and an anti-proliferative agent |
| 04/08/2008 | US7354577 Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof |
| 04/08/2008 | CA2394699C Device for injection of antiparasitic agents in domestic animals |
| 04/08/2008 | CA2349620C Use of aliphatic polyamines for reducing oxalate |
| 04/08/2008 | CA2304819C Perforated microparticles and methods of use |
| 04/08/2008 | CA2295588C Nanocrystalline formulations of human immunodeficiency virus (hiv) protease inhibitors using cellulosic surface stabilizers and methods of making such formulations |
| 04/08/2008 | CA2232663C At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys |
| 04/03/2008 | WO2008039863A2 Composition comprising a melanocortin receptor (mcr) modulating agent alone or in combination with a second neurogenic agent for treating nervous system disorders |
| 04/03/2008 | WO2008039514A1 Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration |
| 04/03/2008 | WO2008038841A1 Thiadiazolone derivative and use thereof |
| 04/03/2008 | WO2008038832A1 Therapeutic agent, detection method and detection kit for breast cancer and ovarian cancer |
| 04/03/2008 | WO2008038600A1 1,4-benzodiazepine derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes |
| 04/03/2008 | WO2008038587A1 Cd20-negatively converted b cell malignant lymphocyte cell line and utilization of the same |
| 04/03/2008 | WO2008038304A2 Therapeutical formulation comprising an alpha-glucosidase inhibitor and a nitric oxide scavenger. |
| 04/03/2008 | WO2008038303A2 Therapeutic formulation comprising a sulfonylurea, a thiazolidinedione and a nitric oxide scavenger. |
| 04/03/2008 | WO2008038302A2 Therapeutic formulation comprising a sulfonylurea, metformin and a nitric oxide scavenger. |
| 04/03/2008 | WO2008037262A1 Wound healing composition comprising phosphate, iron and copper |
| 04/03/2008 | WO2008021124A3 Compositions and drug-delivery systems comprising rapamycin analogs and paclitaxel |
| 04/03/2008 | WO2008000731A3 Pharmaceutical composition for the oral administration of omega polyenoic fatty acids |
| 04/03/2008 | WO2007146983A3 Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury |
| 04/03/2008 | WO2007057440A3 Improved methods of using phosphoantigen for the treatment of cancer |
| 04/03/2008 | US20080081825 5-((2,4-difluorophenyl) {[(1-methyl-4-piperidinyl)oxy]imino}methyl)-1-(2,6-dimethylphenyl)-2(1H)-pyridinone; p38 MAP kinase and tumor necrosis factor inhibitor; inflammatory cytokines or chemokine, respiratory diseases, cardiovascular diseases and bone diseases |
| 04/03/2008 | US20080081794 Smg-1 binding protein and screening method for substances that can regulate the activity thereof |
| 04/03/2008 | US20080081082 Topical Skin Compositions, Their Preparation, and Their Use |
| 04/03/2008 | US20080081034 Topical Skin Compositions, Their Preparation, and Their Use |
| 04/03/2008 | DE102006046745A1 Use of spirocyclic cyclohexane-derivative exhibiting an affinity for opioid-receptor and opioid receptor-like-1-receptor, for producing a medicament e.g. for treating diabetic neuropathy, for narcosis or for analgesia during narcosis |
| 04/03/2008 | CA2661576A1 Stabilizing compositions for antibiotics and methods of use |
| 04/02/2008 | EP1906184A1 Diagnostic agent and therapeutic agent for disease related to macrocyte and macrophage |
| 04/02/2008 | EP1905832A2 Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions |
| 04/02/2008 | EP1905829A2 Templated molecules and methods for using such molecules |
| 04/02/2008 | EP1905457A1 Angiogenesis and vascular permeability modulators and inhibitors |
| 04/02/2008 | EP1905452A1 Agent for prevention or treatment of glaucoma |
| 04/02/2008 | EP1905451A1 Combinations comprising antimuscarinic agents and corticosteroids |
| 04/02/2008 | EP1905450A1 Pharmaceutical composition containing ppar gamma agonist |
| 04/02/2008 | EP1905446A1 Use of PYY analogs and antagonists of PPY receptors for manipulating satiety |
| 04/02/2008 | EP1905309A1 Uses of oil bodies |
| 04/02/2008 | EP1904180A2 Pharmaceutical dosage form containing an active principle combination of nifedipine and/or nisoldipine and of an angiotensin ii antagonist |
| 04/02/2008 | EP1904108A2 Formulation and method for administration of ophthalmologically active agents |
| 04/02/2008 | EP1904107A2 Use of inhibitors of histone deacetylases in combination with nsaid for the therapy of cancer and/or inflammatory diseases |
| 04/02/2008 | EP1904077A1 Method for modulating responsiveness to steroids |
| 04/02/2008 | EP1904070A1 Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells |
| 04/02/2008 | EP1904058A2 Combination of a dpp-iv inhibitor and a cannabinoid cb1 receptor antagonist |
| 04/02/2008 | EP1904050A2 Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy |
| 04/02/2008 | EP1904046A2 Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| 04/02/2008 | EP1904014A2 Wound dressing and methods of making and using the same |
| 04/02/2008 | EP1446160B1 Aspirin-containing transdermal pharmaceutical composition for the treatment of calcification |
| 04/02/2008 | EP1424898A4 Treatment of cancers by inhalation of stable platinum-containing formulations |
| 04/02/2008 | EP1424889A4 Method for treating lung cancers |
| 04/02/2008 | EP1397153B1 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 04/02/2008 | EP1311260B1 Lipase inhibitors to treat dyspepsia |
| 04/02/2008 | EP1244466B1 ACTIVATION OF THE IMMUNE SYSTEM BY AN NF-kappaB INDUCER AND AN ANTIGEN |
| 04/02/2008 | EP1009824B1 COMPOSITIONS AND METHODS FOR MODULATING CELLULAR NF-kappaB ACTIVATION |
| 04/02/2008 | EP0951282B1 Prevention and treatment of skeletal disorder with ep2 receptor subtype selective prostaglandin e2 agonists |
| 04/02/2008 | CN101155923A Method for producing probiotically derived compounds |